Trading November 17, 2026

Mayne Pharma shares jump after Gedeon Richter takeover agreement

Mayne Pharma shares jump after Gedeon Richter takeover agreement
Mayne PharmaGedeon RichtertakeoverASXpharmaceuticalswomen's healthscheme implementation deedmerger

Mayne Pharma stock climbed almost 81% to A$5.805 on Tuesday after the company said it had signed a scheme implementation deed with Hungarian drugmaker Gedeon Richter.

Richter will buy all outstanding Mayne Pharma shares for A$6.40 in cash each, valuing the company’s equity at approximately A$604 million. The offer is a 99.4% premium to Mayne Pharma’s 16 November closing price and a 124% premium to its 30-day volume weighted average price.

The scheme is fully funded and subject to customary conditions, including shareholder approval at the scheme meeting and completion of Mayne Pharma’s previously announced sale of its international business segment to Evaris Pharma. In the absence of a superior proposal, the board unanimously recommends that shareholders vote in favour.

The three largest shareholders — Funicular Funds, Bruce Mathieson and Trium Capital — have indicated they support the transaction, together holding about 22.14% of Mayne Pharma’s ordinary shares. Gedeon Richter said the acquisition gives it a US women’s health portfolio and sales footprint, including its estetrol-based contraceptive pill.

Mayne Pharma outpaced a subdued ASX 200 index.

This article was produced with AI assistance and reviewed by an editor. Further information is available in our terms and conditions.

FractLab Unlock Your Edge A proprietary strategy built to surface hidden opportunities others miss. FractLab Trade with FractLab Multi-timeframe trend detection, accumulation filters and adaptive position scaling. FractLab Try it with a guarantee Full TradingView toolkit access. 30-day money back if it is not for you. Try